Replimune Group, Inc. (REPL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Replimune Group, Inc. (REPL) Healthcare & Pipeline Overview

Replimune Group, Inc. pioneers oncolytic immuno-gene therapies, leveraging its proprietary Immunotherapy platform to combat cancer. With lead candidate RP1 in Phase I/II and Phase II trials, and RP2 and RP3 in Phase I, the company targets solid tumors and cutaneous squamous cell carcinoma, positioning itself in the competitive biotechnology landscape.

What Is the Investment Thesis for REPL?

The company's lead candidate, RP1, is currently in Phase I/II and Phase II clinical trials, targeting a range of solid tumors and cutaneous squamous cell carcinoma, respectively. Success in these trials could drive significant value. Further potential lies in the development of RP2 and RP3, both in Phase I clinical trials, expanding the company's pipeline and addressing different mechanisms of immune activation. However, the biotechnology sector is inherently risky, with clinical trial outcomes and regulatory approvals posing significant uncertainties. With a market capitalization of $1.11B, Replimune's valuation reflects both the potential upside and the inherent risks associated with its developmental stage and the broader biotechnology industry.

Based on FMP financials and quantitative analysis

REPL Key Highlights

RP1, Replimune's lead product candidate, is in Phase I/II clinical trials for a range of solid tumors, indicating progress in its development pipeline.

• RP1 is also in Phase II clinical trials for patients with cutaneous squamous cell carcinoma, potentially addressing a specific market need.
• The company is developing RP2 and RP3, both in Phase I clinical trials, expanding its portfolio of oncolytic immuno-gene therapies.
• Replimune's proprietary Immunotherapy platform is a key asset, enabling the design and development of novel cancer treatments.
• The company employs 479 individuals, reflecting its investment in research and development activities.

Who Are REPL's Competitors?

REPL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are REPL's Key Strengths?

Proprietary Immunotherapy platform.

• Promising clinical trial results for RP1.
• Pipeline of multiple oncolytic immuno-gene therapy candidates.
• Experienced management team.

What Are REPL's Weaknesses?

Limited commercialized products and revenue.

• Reliance on clinical trial success and regulatory approvals.
• High research and development costs.
• Competition from larger pharmaceutical companies.

What Could Drive REPL Stock Higher?

Data readout from Phase I/II clinical trials of RP1 for solid tumors.

• Data readout from Phase II clinical trial of RP1 for cutaneous squamous cell carcinoma.
• Advancement of RP2 and RP3 into later-stage clinical trials.
• Expansion of clinical trial sites and patient enrollment.
• Potential for strategic partnerships and collaborations.

What Are the Key Risks for REPL?

Financial-distress signal — its Altman Z-Score of -5.47 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory setbacks or rejection of product candidates.
• Competition from other cancer therapies.
• High research and development costs.
• Dependence on key personnel and intellectual property.

What Are the Growth Opportunities for REPL?

• Expansion of RP1 Clinical Trials: A significant growth opportunity lies in expanding the clinical trials for RP1 to include additional solid tumor types and stages. Positive results from these trials could lead to accelerated regulatory approval and broader market access. The global market for solid tumor therapies is estimated to reach $400 billion by 2028, providing a substantial addressable market for RP1 if it proves effective and safe.
• Advancement of RP2 and RP3 Programs: The successful advancement of RP2 and RP3 through clinical trials represents another key growth opportunity. These product candidates target different mechanisms of immune activation, potentially broadening Replimune's therapeutic reach and addressing unmet needs in cancer treatment. The market for immunotherapies is projected to continue growing rapidly, driven by their effectiveness in treating various cancers.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could provide Replimune with access to additional resources, expertise, and funding. Collaborations can accelerate the development and commercialization of its product candidates, as well as expand its research capabilities. Such partnerships are common in the biotechnology industry and can significantly enhance a company's growth prospects.
• Geographic Expansion: Expanding its operations and clinical trials to new geographic regions, particularly in Asia and Europe, represents a growth opportunity for Replimune. These regions have large patient populations and growing healthcare markets. Establishing a presence in these markets could increase the company's revenue potential and diversify its geographic risk.
• Acquisition or Licensing of New Technologies: Acquiring or licensing new technologies that complement its existing platform could enhance Replimune's competitive position and expand its product pipeline. This could include technologies related to gene therapy, immunotherapy, or drug delivery. Such acquisitions can provide access to new intellectual property and expertise, accelerating the development of innovative cancer therapies.

What Are REPL's Competitive Advantages?

• Proprietary Immunotherapy platform for developing oncolytic viruses.
• Patent protection for its product candidates and technologies.
• Clinical trial data demonstrating the efficacy and safety of its therapies.
• Expertise in oncolytic virus development and immuno-oncology.

What Does REPL Do?

Replimune Group, Inc., founded in 2015 and headquartered in Woburn, Massachusetts, is a biotechnology company dedicated to developing oncolytic immuno-gene therapies for the treatment of cancer. The company operates on its proprietary Immunotherapy platform, which is used to design and develop product candidates aimed at activating the immune system against cancer cells. Replimune's lead product candidate, RP1, is a selectively replicating version of the herpes simplex virus 1 (HSV-1). RP1 is currently undergoing Phase I/II clinical trials for a range of solid tumors and a Phase II clinical trial for patients with cutaneous squamous cell carcinoma (CSCC). In addition to RP1, Replimune is developing RP2, which is in Phase I clinical trials and is designed to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response caused by CTLA-4. The company is also developing RP3, which is in Phase I clinical trials and is engineered to express immune-activating proteins that stimulate T cells. Replimune's focus on innovative immuno-gene therapies positions it within the competitive landscape of the biotechnology industry, where it aims to address unmet needs in cancer treatment.

What Products and Services Does REPL Offer?

• Develop oncolytic immuno-gene therapies for cancer treatment.
• Utilize a proprietary Immunotherapy platform to design product candidates.
• Focus on activating the immune system against cancer cells.
• Conduct clinical trials for various product candidates.
• Develop RP1, a selectively replicating version of herpes simplex virus 1.
• Develop RP2, designed to block the inhibition of the immune response caused by CTLA-4.
• Develop RP3, engineered to express immune-activating proteins that stimulate T cells.

How Does REPL Make Money?

• Develop and commercialize oncolytic immuno-gene therapies.
• Generate revenue through the sale of approved therapies.
• Potentially generate revenue through licensing agreements and partnerships.
• Fund research and development through venture capital and public offerings.

What Industry Does REPL Operate In?

Replimune Group, Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant growth potential. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like Replimune are at the forefront of developing innovative treatments, including oncolytic viruses and immuno-gene therapies. The competitive landscape includes both established pharmaceutical companies and smaller biotechnology firms, all vying for market share in this rapidly evolving field. Success hinges on clinical trial outcomes, regulatory approvals, and the ability to effectively commercialize novel therapies.

Who Are REPL's Key Customers?

• Hospitals and cancer treatment centers.
• Oncologists and other healthcare professionals.
• Patients with various types of cancer.
• Potential pharmaceutical partners for licensing and collaboration.

Replimune Group, Inc. (REPL) Valuation Context

Valued at $1.11B, REPL is classified as a small-cap stock. Analyst price targets span from $17.00 to $20.00, with a consensus of $18.67. At the current price of $13.24, that implies approximately 41% upside potential. Relative to its peer group, REPL's quantitative score of 26/100 is below the peer average of 75/100.

REPL Revenue & Earnings Trend

In Q1 FY2027, REPL generated $0 in top-line revenue. The company recorded a net loss of $69.8M, with diluted EPS of $-0.72. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, REPL averaged $-0.80 in diluted EPS.

Company Profile

Replimune Group, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Woburn, US. The company is led by CEO Sushil Patel. REPL has traded publicly since 2018.

Key Financial Metrics

Return on assets is -94.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -30.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.60 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -30.7%, the inverse of the P/E and a quick read on earnings relative to price.

Replimune Group, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.47 places it in the distress zone, a signal of elevated financial risk.

Replimune Group, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 4.9% below estimates on average.

Over the past six months, Replimune Group, Inc. insiders filed 15 SEC Form 4 transactions — 13 sales and 2 purchases. On net that is roughly 2.5M shares acquired (about $1.6M) — insiders putting money in tends to read as conviction.

REPL Financials

REPL Latest News

REPL Analyst Consensus

REPL MoonshotScore

Latest Replimune Group, Inc. Analysis

What Investors Ask About Replimune Group, Inc. (REPL) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources